Group 1 - The company, Shenghe Biotech-B (02898), announced the appointment of Zhonghui Anda Certified Public Accountants as the new auditor starting from September 16, 2025 [1] - This decision follows the resignation of Deloitte, filling the temporary vacancy left by their departure [1] - The term of the new auditor will last until the conclusion of the company's next annual general meeting [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Sunho Biologics, Inc. 盛 禾 生 物 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2898） 委任核數師 本公告乃由盛禾生物控股有限公司（「本公司」）董事（「董事」）會（「董事會」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.51 (4)條作出。 董事會謹此熱烈歡迎中匯安達獲委任為新核數師。 承董事會命 盛禾生物控股有限公司 主席兼執行董事 茲 提述 本公 司 日期 為2025 年 9 月 15 日 的公 告， 內容 有 關德 勤‧ 關 黃陳 方會 計 師行 （「德勤」）辭任本公司核數師（「該公告」）。除另有界定者外，本公告所用詞彙與該 公告所界定者具有相同涵義。 在德勤辭任核數師前，審核委員會已取得並審閱德勤及其他專業會計師事務所提 供的審核建議，並已考慮多項因素，包括 ...

Group 1 - The company Shenghe Biotechnology-B (02898) announced the resignation of its auditor, Deloitte, effective immediately [1] - The reason for Deloitte's resignation is the failure to reach an agreement on the audit fees for the company's consolidated financial statements for the year ending December 31, 2025 [1]

Group 1 - The company announced the resignation of its auditor, Deloitte, effective September 9, 2025 [1]

Core Viewpoint - Deloitte has resigned as the auditor for Shenghe Bio-B (02898) effective immediately due to a failure to reach an agreement on the audit fees for the consolidated financial statements for the year ending December 31, 2025 [1] Group 1 - Deloitte submitted a resignation letter dated September 9, 2025 [1] - The resignation is effective immediately [1] - The reason for the resignation is the inability to agree on audit fees for the company and its subsidiaries [1]

董事會謹此宣佈，德勤‧關黃陳方會計師行（「德勤」）已提呈其日期為2025年9月9 日的辭任函件（「辭任函件」），據此，德勤已辭任本公司核數師（「核數師」）一職， 即時生效，原因為本公司未能就審核本公司及其附屬公司（「本集團」）截至2025年 12月31日止年度的綜合財務報表的審核費用與德勤達成共識。董事會及本公司審 核委員會（「審核委員會」）已審閱德勤提供的審核建議及其他專業會計師事務所提 供的審核建議，並已考慮彼等各自的行業經驗、技術知識、資源分配、往績記錄 及建議費用。鑑於其他專業會計師事務所提供的建議更具競爭力，董事會及審核 委員會認為更換核數師將提高本公司審核工作的成本效益。 德勤於辭任函件中確認，概無與其辭任有關的事宜須提請本公司股東（「股東」）垂 注。董事會及審核委員會亦已確認，除上文所披露的審核費用外，德勤與本公司 並無其他意見分歧，亦無其他有關更換核數師的事宜須提請股東垂注。 於本公告日期，董事會確認，德勤尚未就本集團截至2025年12月31日止年度的綜 合財務報表展開任何審核工作。因此，預期更換核數師將不會對本集團截至2025 年12月31日止年度的年度審核工作構成任何重大影響。 – 1 – ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 盛禾生物控股有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02898 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000 | USD | | 0.0005 | USD | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 200,000,000 | USD | | 0.0005 | USD | | 100,000 | FF301 第 1 頁 ...

Core Viewpoint - Shenghe Biotechnology-B (02898.HK) reported a significant increase in other income and a reduction in R&D expenses, but also experienced a rise in losses for the six months ending June 30, 2025 compared to the same period in 2024 [1] Financial Performance - Other income increased by 178% from approximately RMB 1.8 million for the six months ending June 30, 2024 to approximately RMB 5.0 million for the reporting period, primarily due to increased interest income from financial institutions [1] - R&D expenses decreased from approximately RMB 37.7 million in the first half of 2024 to approximately RMB 28.8 million in the reporting period, mainly due to a reduction in share-based compensation [1] - Losses for the period increased from approximately RMB 36.1 million for the six months ending June 30, 2024 to approximately RMB 38.2 million for the reporting period [1]

Group 1 - The company Shenghe Biotechnology-B (02898) reported its interim results for 2025, showing other income of 5.035 million, which represents a year-on-year increase of 182.55% [1] - The company recorded a net loss of 38.199 million, reflecting a year-on-year increase of 5.88% [1] - The loss per share was reported at 0.25 yuan [1]

Group 1 - The company Shenghe Biotechnology-B (02898) reported its mid-year results for 2025, showing other income of 5.035 million, which represents a year-on-year increase of 182.55% [1] - The net loss for the company was 38.199 million, reflecting a year-on-year increase of 5.88% [1] - The loss per share was reported at 0.25 yuan [1]